ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO013

Renal Injury and Inflammatory Response in New Onset IgA Nephropathy After Infection With SARS-CoV-2 or COVID-19 Vaccination

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Hussein, Naser, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany
  • Vonbrunn, Eva, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany
  • Amann, Kerstin U., Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany
  • Daniel, Christoph, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Bayern, Germany

After infection with SARS-Cov-2 or vaccination against COVID-19, some patients develop kidney diseases, including minimal change nephrotic syndrome and IgA Nephropathy (IgAN). Here we characterized renal injury and inflammatory response in biopsies from patients with new onset IgAN diagnosed promptly after COVID-19 disease or vaccination.


Eleven kidney biopsies from patients who developed IgAN after SARS-Cov-2 infection and 6 from patients with new onset IgAN after vaccination against COVID-19 were diagnosed at Dep. of Nephropathology, FAU Erlangen-Nuremberg. Biopsies from patients with IgAN who had no prior COVID-19 disease (n=10) and zero-time biopsies from transplants (ZB; n=6) served as controls. Serum creatinine was assessed and kidney injury by analysis of podocyte loss, detection of Pax-8 positive parietal epithelial cells on the glomerular tuft and IF/TA. Macrophages and granulocytes were detected by triple staining of CD68, CD163 and myeloperoxidase.


Significant podocyte loss, as assessed by nephrin staining, was observed in all three IgAN groups compared to ZB, as well as Pax8-positve parietal epithelial cells on glomerular tuft. The serum creatinine, as a marker of kidney function, was on average 1.8-3.5-fold higher in the IgAN groups compared to ZB, but did not reach significance level due to small sample numbers. IF/TA was below 20% in most investigated biopsies. No significant differences in renal function or injury were observed between different IgAN groups. While CD68+CD163+MPO+, CD68+CD163-MPO+ and CD68+CD163+MPO- (M2c-like macrophages) inflammatory cells were significantly increased in both COVID-19 IgAN groups, significant increase of CD68-CD163+MPO- cells compared to ZB control was restricted to IgAN w/o COVID-19 group (11.7±8.1 vs 0.8±0.9 cells / mm2). CD68+CD163-MPO- M1-like macrophages and CD68-CD163-MPO+ neutrophils tended to be higher in all IgAN groups but failed to reach the level of significance.


Changes in kidney function and renal damage was comparable in all three investigated IgAN groups independent on experience of COVID-19 or vaccination. Renal macrophage and neutrophil invasion tended to by higher in COVID-19 IgAN groups. However, no significant differences in inflammatory were observed in direct comparisons of IgAN groups.


  • Other NIH Support